Cargando…
The Novel RXR Agonist MSU-42011 Differentially Regulates Gene Expression in Mammary Tumors of MMTV-Neu Mice
Retinoid X receptor (RXR) agonists, which activate the RXR nuclear receptor, are effective in multiple preclinical cancer models for both treatment and prevention. While RXR is the direct target of these compounds, the downstream changes in gene expression differ between compounds. RNA sequencing wa...
Autores principales: | Reich, Lyndsey A., Leal, Ana S., Ellsworth, Edmund, Liby, Karen T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001983/ https://www.ncbi.nlm.nih.gov/pubmed/36901727 http://dx.doi.org/10.3390/ijms24054298 |
Ejemplares similares
-
The RXR Agonist MSU42011 Is Effective for the Treatment of Preclinical HER2+ Breast Cancer and Kras-Driven Lung Cancer
por: Leal, Ana S., et al.
Publicado: (2021) -
The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer
por: Moerland, Jessica A., et al.
Publicado: (2020) -
Mechanism of Inhibition of MMTV-neu and MMTV-wnt1 induced mammary oncogenesis by RARα agonist AM580
por: Lu, Yongke, et al.
Publicado: (2010) -
Mammary glands exhibit molecular laterality and undergo left-right asymmetric ductal epithelial growth in MMTV-cNeu mice
por: Robichaux, Jacqulyne P., et al.
Publicado: (2014) -
MMTV-NeuT/ATTAC mice: a new model for studying the stromal tumor microenvironment
por: Yuan, Hongyan, et al.
Publicado: (2018)